Aldeyra Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aldeyra Therapeutics's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-2.6%
Earnings growth rate
20.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | -31.3% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aldeyra Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -38 | 13 | 29 |
30 Sep 23 | 0 | -46 | 16 | 34 |
30 Jun 23 | 0 | -52 | 17 | 39 |
31 Mar 23 | 0 | -61 | 17 | 46 |
31 Dec 22 | 0 | -62 | 15 | 47 |
30 Sep 22 | 0 | -65 | 13 | 51 |
30 Jun 22 | 0 | -66 | 13 | 53 |
31 Mar 22 | 0 | -63 | 12 | 49 |
31 Dec 21 | 0 | -58 | 11 | 45 |
30 Sep 21 | 0 | -53 | 11 | 39 |
30 Jun 21 | 0 | -46 | 11 | 32 |
31 Mar 21 | 0 | -39 | 10 | 26 |
31 Dec 20 | 0 | -38 | 10 | 25 |
30 Sep 20 | 0 | -39 | 11 | 27 |
30 Jun 20 | 0 | -49 | 11 | 37 |
31 Mar 20 | 0 | -55 | 12 | 43 |
31 Dec 19 | 0 | -61 | 12 | 44 |
30 Sep 19 | 0 | -58 | 11 | 43 |
30 Jun 19 | 0 | -50 | 12 | 35 |
31 Mar 19 | 0 | -46 | 11 | 31 |
31 Dec 18 | 0 | -39 | 10 | 30 |
30 Sep 18 | 0 | -35 | 9 | 27 |
30 Jun 18 | 0 | -29 | 7 | 22 |
31 Mar 18 | 0 | -26 | 6 | 20 |
31 Dec 17 | 0 | -22 | 6 | 16 |
30 Sep 17 | 0 | -20 | 6 | 14 |
30 Jun 17 | 0 | -20 | 6 | 14 |
31 Mar 17 | 0 | -19 | 6 | 13 |
31 Dec 16 | 0 | -19 | 6 | 13 |
30 Sep 16 | 0 | -18 | 6 | 13 |
30 Jun 16 | 0 | -17 | 5 | 12 |
31 Mar 16 | 0 | -15 | 5 | 10 |
31 Dec 15 | 0 | -12 | 4 | 8 |
30 Sep 15 | 0 | -10 | 4 | 6 |
30 Jun 15 | 0 | -9 | 4 | 5 |
31 Mar 15 | 0 | -12 | 4 | 4 |
31 Dec 14 | 0 | -10 | 4 | 4 |
30 Sep 14 | 0 | -6 | 3 | 3 |
30 Jun 14 | 0 | -3 | 3 | 2 |
31 Mar 14 | 0 | 5 | 3 | 2 |
31 Dec 13 | 0 | 1 | 2 | 2 |
Quality Earnings: 137 is currently unprofitable.
Growing Profit Margin: 137 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 137 is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.
Accelerating Growth: Unable to compare 137's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 137 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 137 has a negative Return on Equity (-31.34%), as it is currently unprofitable.